Nonalcoholic fatty liver disease: 30 years research changed NASH;Stéatohépatite métabolique : 30 ans de recherches qui ont changé la NASH

Gastroenterologie Clinique et Biologique

Volumn 33, Issue 8-9, 2009, Pages 850-858

  Ratziu, V ^a   Poynard, T ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABDOMINAL OBESITY; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; DISEASE SEVERITY; HUMAN; HYPERFERRITINEMIA; HYPERTENSION; INSULIN RESISTANCE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER FIBROSIS; MORTALITY; NONALCOHOLIC FATTY LIVER; SHORT SURVEY;

BIOMEDICAL RESEARCH; DECISION TREES; FATTY LIVER; HUMANS; TIME FACTORS;

EID: 70349179251     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gcb.2009.05.001     Document Type: Short Survey

References (83)

1. Ludwig J., Viggiano T., McGill D.B., and Ott B.J. Nonalcoholic steatohepatitis. Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 55 (1980) 434-438
2. Diehl A.M., Goodman Z., and Ishak K.G. Alcohollike liver disease in nonalcoholics. A clinical and histologic comparison with alcohol-induced liver injury. Gastroenterology 95 (1988) 1056-1062
3. Pinto H.C., Baptista A., Camilo M.E., Valente A., Saragoca A., and de Moura M.C. Nonalcoholic steatohepatitis. Clinicopathological comparison with alcoholic hepatitis in ambulatory and hospitalized patients. Dig Dis Sci 41 (1996) 172-179
4. Itoh S., Yougel T., and Kawagoe K. Comparison between nonalcoholic steatohepatitis and alcoholic hepatitis. Am J Gastroenterol 82 (1987) 650-654
5. Cortez-Pinto H., Baptista A., Camilo M.E., and De Moura M.C. Nonalcoholic steatohepatitis--a long-term follow-up study: comparison with alcoholic hepatitis in ambulatory and hospitalized patients. Dig Dis Sci 48 (2003) 1909-1913
6. Sanyal A.J., Campbell-Sargent C., Mirshahi F., Rizzo W.B., Contos M.J., Sterling R.K., et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 120 (2001) 1183-1192
7. Marchesini G., Brizi M., Bianchi G., Tomassetti S., Bugianesi E., Lenzi M., et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 50 (2001) 1844-1850
8. Marchesini G., Brizi M., Morselli-Labate A.M., Bianchi G., Bugianesi E., McCullough A.J., et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 107 (1999) 450-455
9. Ratziu V., Giral P., Charlotte F., Bruckert E., Thibault V., Theodorou I., et al. Liver fibrosis in overweight patients. Gastroenterology 118 (2000) 1117-1123
10. Dixon J.B., Bhathal P.S., and O'Brien P.E. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 121 (2001) 91-100
11. Marchesini G., Bugianesi E., Forlani G., Cerrelli F., Lenzi M., Manini R., et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 37 (2003) 917-923
12. El-Serag H.B., Tran T., and Everhart J.E. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 126 (2004) 460-468
13. Powell E.E., Jonsson J.R., and Clouston A.D. Steatosis: co-factor in other liver diseases. Hepatology 42 (2005) 5-13
14. Hui J.M., Sud A., Farrell G.C., Bandara P., Byth K., Kench J.G., et al. Insulin resistance is associated with chronic hepatitis C and virus infection fibrosis progression. Gastroenterology 125 (2003) 1695-1704
15. Fartoux L., Chazouilleres O., Wendum D., Poupon R., and Serfaty L. Impact of steatosis on progression of fibrosis in patients with mild hepatitis C. Hepatology 41 (2005) 82-87
16. Naveau S., Giraud V., Borotto E., Aubert A., Capron F., and Chaput J.C. Excess weight is a risk factor for alcoholic liver disease. Hepatology 25 (1997) 108-111
17. Raynard B., Balian A., Fallik D., Capron F., Bedossa P., Chaput J.C., et al. Risk factors of fibrosis in alcohol-induced liver disease. Hepatology 35 (2002) 635-638
18. Powell E.E., Ali A., Clouston A.D., Dixon J.L., Lincoln D.J., Purdie D.M., et al. Steatosis is a cofactor in liver injury in hemochromatosis. Gastroenterology 129 (2005) 1937-1943
19. Wong G.L., Wong V.W., Choi P.C., Chan A.W., Chim A.M., Yiu K.K., et al. Metabolic syndrome increases the risk of liver cirrhosis in chronic hepatitis B. Gut 58 (2009) 111-117
20. Pendino G.M., Mariano A., Surace P., Caserta C.A., Fiorillo M.T., Amante A., et al. Prevalence and etiology of altered liver tests: a population-based survey in a Mediterranean town. Hepatology 41 (2005) 1151-1159
21. Clark J.M., Brancati F.L., and Diehl A.M. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 98 (2003) 960-967
22. Ruhl C.E., and Everhart J.E. Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. Gastroenterology 124 (2003) 71-79
23. Suzuki A., Angulo P., Lymp J., St Sauver J., Muto A., Okada T., et al. Chronological development of elevated aminotransferases in a nonalcoholic population. Hepatology 41 (2005) 64-71
24. Bellentani S., Saccoccio G., Masutti F., Croce L.S., Brandi G., Sasso F., et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 132 (2000) 112-117
25. Bellentani S., Bedogni G., Miglioli L., and Tiribelli C. The epidemiology of fatty liver. Eur J Gastroenterol Hepatol 16 (2004) 1087-1093
26. Browning J.D., Szczepaniak L.S., Dobbins R., Nuremberg P., Horton J.D., Cohen J.C., et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 40 (2004) 1387-1395
27. Byron D., and Minuk G.Y. Clinical hepatology: profile of an urban, hospital-based practice. Hepatology 24 (1996) 813-815
28. Weston S.R., Leyden W., Murphy R., Bass N.M., Bell B.P., Manos M.M., et al. Racial and ethnic distribution of nonalcoholic fatty liver in persons with newly diagnosed chronic liver disease. Hepatology 41 (2005) 372-379
29. de Ledinghen V., Ratziu V., Causse X., Le Bail B., Capron D., Renou C., et al. Diagnostic and predictive factors of significant liver fibrosis and minimal lesions in patients with persistent unexplained elevated transaminases. A prospective multicenter study. J Hepatol 45 (2006) 592-599
30. Lee D.H., Ha M.H., and Christiani D.C. Body weight, alcohol consumption and liver enzyme activity--a 4-year follow-up study. Int J Epidemiol 30 (2001) 766-770
31. Adams L.A., Sanderson S., Lindor K.D., and Angulo P. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol 42 (2005) 132-138
32. Fassio E., Alvarez E., Dominguez N., Landeira G., and Longo C. Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. Hepatology 40 (2004) 820-826
33. Ratziu V., and Poynard T. NASH: a hidden and silent fibroser finally revealed?. J Hepatol 42 (2005) 12-14
34. Ratziu V., Bugianesi E., Dixon J., Fassio E., Ekstedt M.F.C., et al. Histological progression of non-alcoholic fatty liver disease: a critical reassessment based on liver sampling variability. Aliment Pharmacol Ther 26 (2007) 821-830
35. Caldwell S.H., and Crespo D.M. The spectrum expanded: cryptogenic cirrhosis and the natural history of non-alcoholic fatty liver disease. J Hepatol 40 (2004) 578-584
36. Caldwell S.H., Oelsner D.H., Iezzoni J.C., Hespenheide E.E., Battle E.H., and Driscoll C.J. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 29 (1999) 664-669
37. Marrero J.A., Fontana R.J., Su G.L., Conjeevaram H.S., Emick D.M., and Lok A.S. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology 36 (2002) 1349-1354
38. Ratziu V., Bonyhay L., Di Martino V., Charlotte F., Cavallaro L., Sayegh-Tainturier M.H., et al. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology 35 (2002) 1485-1493
39. Bugianesi E., Leone N., Vanni E., Marchesini G., Brunello F., Carucci P., et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 123 (2002) 134-140
40. El-Serag H.B., Hampel H., and Javadi F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol 4 (2006) 369-380
41. Inoue M., Iwasaki M., Otani T., Sasazuki S., Noda M., and Tsugane S. Diabetes mellitus and the risk of cancer: results from a large-scale population-based cohort study in Japan. Arch Intern Med 166 (2006) 1871-1877
42. Lai M.S., Hsieh M.S., Chiu Y.H., and Chen T.H. Type 2 diabetes and hepatocellular carcinoma: a cohort study in high prevalence area of hepatitis virus infection. Hepatology 43 (2006) 1295-1302
43. Balkau B., Kahn H.S., Courbon D., Eschwege E., and Ducimetiere P. Hyperinsulinemia predicts fatal liver cancer but is inversely associated with fatal cancer at some other sites: the Paris Prospective Study. Diabetes Care 24 (2001) 843-849
44. Jee S.H., Ohrr H., Sull J.W., Yun J.E., Ji M., and Samet J.M. Fasting serum glucose level and cancer risk in Korean men and women. JAMA 293 (2005) 194-202
45. Rapp K., Schroeder J., Klenk J., Ulmer H., Concin H., Diem G., et al. Fasting blood glucose and cancer risk in a cohort of more than 140 000 adults in Austria. Diabetologia 49 (2006) 945-952
46. Calle E.E., Rodriguez C., Walker-Thurmond K., and Thun M.J. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U, S. adults. N Engl J Med 348 (2003) 1625-1638
47. Samanic C., Chow W.H., Gridley G., Jarvholm B., and Fraumeni Jr. J.F. Relation of body mass index to cancer risk in 362,552 Swedish men. Cancer Causes Control 17 (2006) 901-909
48. Batty G.D., Shipley M.J., Kivimaki M., Barzi F., Smith G.D., Mitchell R., et al. Obesity and overweight in relation to liver disease mortality in men: 38 year follow-up of the original Whitehall study. Int J Obes 32 (2008) 1741-1744
49. Jee S.H., Yun J.E., Park E.J., Cho E.R., Park I.S., Sull J.W., et al. Body mass index and cancer risk in Korean men and women. Int J Cancer 123 (2008) 1892-1896
50. Larsson S.C., and Wolk A. Overweight, obesity and risk of liver cancer: a meta-analysis of cohort studies. Br J Cancer 97 (2007) 1005-1008
51. Ratziu V., and Poynard T. Assessing the outcome of nonalcoholic steatohepatitis? It's time to get serious. Hepatology 44 (2006) 802-805
52. Dam-Larsen S., Franzmann M., Andersen I.B., Christoffersen P., Jensen L.B., Sorensen T.I., et al. Long term prognosis of fatty liver: risk of chronic liver disease and death. Gut 53 (2004) 750-755
53. Ekstedt M., Franzen L.E., Mathiesen U.L., Thorelius L., Holmqvist M., Bodemar G., et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 44 (2006) 865-873
54. Adams L.A., Lymp J.F., St Sauver J., Sanderson S.O., Lindor K.D., Feldstein A., et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 129 (2005) 113-121
55. Ong J.P., Pitts A., and Younossi Z.M. Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. J Hepatol 49 (2008) 608-612
56. Jepsen P., Vilstrup H., Mellemkjaer L., Thulstrup A.M., Olsen J.H., Baron J.A., et al. Prognosis of patients with a diagnosis of fatty liver--a registry-based cohort study. Hepatogastroenterology 50 (2003) 2101-2104
57. Poynard T., Morra R., Halfon P., Castera L., Ratziu V., Imbert-Bismut F., et al. Meta-analyses of FibroTest diagnostic value in chronic liver disease. BMC Gastroenterol 7 (2007) 40
58. Ratziu V., Massard J., Charlotte F., Messous D., Imbert-Bismut F., Bonyhay L., et al. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol 6 (2006) 6
59. Cales P., Laine F., Boursier J., Deugnier Y., Moal V., Oberti F., et al. Comparison of blood tests for liver fibrosis specific or not to NAFLD. J Hepatol 50 (2009) 165-173
60. Angulo P., Hui J.M., Marchesini G., Bugianesi E., George J., Farrell G.C., et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 45 (2007) 846-854
61. Guha I.N., Parkes J., Roderick P., Chattopadhyay D., Cross R., Harris S., et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology 47 (2008) 455-460
62. Harrison S.A., Oliver D., Arnold H.L., Gogia S., and Neuschwander-Tetri B.A. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut 57 (2008) 1441-1447
63. Jacqueminet S., Lebray P., Morra R., Munteanu L., Messous D., et al. Screening for liver fibrosis by using a noninvasive biomarker in patients with diabetes. Clin Gastroenterol Hepatol 6 (2008) 828-831
64. Ratziu V., Giral P., Munteanu M., Messous D., Mercadier A., Bernard M., et al. Screening for liver disease using non-invasive biomarkers (FibroTest, SteatoTest and NashTest) in patients with hyperlipidaemia. Aliment Pharmacol Ther 25 (2007) 207-218
65. Yoneda M., Mawatari H., Fujita K., Endo H., Iida H., Nozaki Y., et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD). Dig Liver Dis 40 (2008) 371-378
66. Roulot D., Czernichow S., Le Clesiau H., Costes J.L., Vergnaud A.C., and Beaugrand M. Liver stiffness values in apparently healthy subjects: influence of gender and metabolic syndrome. J Hepatol 48 (2008) 606-613
67. Poynard T., Ratziu V., Charlotte F., Messous D., Munteanu M., Imbert-Bismut F., et al. Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol 6 (2006) 34
68. Wieckowska A., Zein N.N., Yerian L.M., Lopez A.R., McCullough A.J., and Feldstein A.E. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology 44 (2006) 27-33
69. Younossi Z.M., Jarrar M., Nugent C., Randhawa M., Afendy M., Stepanova M., et al. A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH). Obes Surg 18 (2008) 1430-1437
70. Poynard T., Ratziu V., Naveau S., Thabut D., Charlotte F., Messous D., et al. The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis. Comp Hepatol 4 (2005) 10
71. Szczepaniak L.S., Nurenberg P., Leonard D., Browning J.D., Reingold J.S., Grundy S., et al. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab 288 (2005) E462-E468
72. Kleiner D.E., Brunt E.M., Van Natta M., Behling C., Contos M.J., Cummings O.W., et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41 (2005) 1313-1321
73. Ratziu V., Charlotte F., Heurtier A., Gombert S., Giral P., Bruckert E., et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 128 (2005) 1898-1906
74. de Marco R., Locatelli F., Zoppini G., Verlato G., Bonora E., and Muggeo M. Cause-specific mortality in type 2 diabetes. The Verona Diabetes Study. Diabetes Care 22 (1999) 756-761
75. Ryysy L., Hakkinen A.M., Goto T., Vehkavaara S., Westerbacka J., Halavaara J., et al. Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients. Diabetes 49 (2000) 749-758
76. Mathurin P., Gonzalez F., Kerdraon O., Leteurtre E., Arnalsteen L., Hollebecque A., et al. The evolution of severe steatosis after bariatric surgery is related to insulin resistance. Gastroenterology 130 (2006) 1617-1624
77. Dixon J.B., Bhathal P.S., Hughes N.R., and O'Brien P.E. Nonalcoholic fatty liver disease: improvement in liver histological analysis with weight loss. Hepatology 39 (2004) 1647-1654
78. Harrison S.A., Fecht W., Brunt E.M., and Neuschwander-Tetri B.A. Orlistat for overweight subjects with nonalcoholic steatohepatitis: a randomized, prospective trial. Hepatology 49 (2009) 80-86
79. Zelber-Sagi S., Nitzan-Kaluski D., Goldsmith R., Webb M., Blendis L., Halpern Z., et al. Long term nutritional intake and the risk for non-alcoholic fatty liver disease (NAFLD): a population based study. J Hepatol 47 (2007) 711-717
80. Zelber-Sagi S., Nitzan-Kaluski D., Goldsmith R., Webb M., Zvibel I., Goldiner I., et al. Role of leisure-time physical activity in nonalcoholic fatty liver disease: a population-based study. Hepatology 48 (2008) 1791-1798
81. Belfort R., Harrison S.A., Brown K., Darland C., Finch J., Hardies J., et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 355 (2006) 2297-2307
82. Ratziu V., Giral P., Jacqueminet S., Charlotte F., Hartemann-Heurtier A., Serfaty L., et al. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology 135 (2008) 100-110
83. Aithal G.P., Thomas J.A., Kaye P.V., Lawson A., Ryder S.D., Spendlove I., et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology 135 (2008) 1176-1184